Zimbabwe has turned down a substantial American healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years due to the United States' insistence on sensitive information.
This move became public after a government memo dated December was leaked, revealing that President Emmerson Mnangagwa believed the agreement was "lopsided".
An official spokesman later explained that the United States was demanding access to biological samples for research and commercial purposes while was not willing to share the benefits from future vaccines.
"We must now begin the challenging and unfortunate task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had donated more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged more dialogue to secure a agreement agreeable to all parties so the nation's critical HIV programme can proceed.
Broader Context
This rejection follows a similar situation in neighbouring Kenya, where a court suspended a related deal with the US following concerns were filed about the safety of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had managed assistance for the US government, but Trump argued its expenditure was "wasteful" and his administration was pursuing direct bilateral deals to boost transparency and accountability.
As per reports, 16 African countries have to date signed these new health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The funds for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation might have yielded extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy via US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"Our nation was requested to provide its biological resources and data indefinitely, without any corresponding promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that provided information," his statement read.
"In essence, our country would provide the raw materials for scientific discovery with no certainty that the final treatments would be accessible to our population if a future health crisis arise."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were disrupting frameworks previously set up via the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to deal with potential pandemics.
"This framework is intended to ensure that when a country contributes its samples, the benefits – including medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," he added.
"We encourage continued dialogue with our US partners on how subsequent collaboration might be structured in a manner that respects the independence and dignity of both nations."
Health Experts Reaction
A leading public health body said it acknowledged the government's concerns, but urged that negotiations should continue since much of the nation's Aids initiatives relied on foreign aid.
"In cases where specific concerns exist, such as those involving information security or implementation frameworks, these can often be addressed via technical clarification and mutually agreed protections," the group said.
The halted deal underscores the ongoing challenges between accepting vital international aid and safeguarding a country's data in an ever more data-driven world.